US 11,793,836 B2
Method for treating complications related to acute or chronic hyperglycemia
Maria Elizabeth De Souza Rodrigues, Atlanta, GA (US); Maria de Lourdes Gamez Tansey, Atlanta, GA (US); Christopher J. Barnum, Detroit, MI (US); Raymond J. Tesi, Martha's Vineyard, MA (US); Dean P. Jones, Atlanta, GA (US); and Douglas I. Walker, Atlanta, GA (US)
Assigned to INmune Bio Inc, Boca Raton, FL (US); and EMORY UNIVERSITY, Atlanta, GA (US)
Appl. No. 16/652,407
Filed by INMUNE BIO INC., La Jolla, CA (US); and EMORY UNIVERSITY, Atlanta, GA (US)
PCT Filed Sep. 27, 2018, PCT No. PCT/US2018/053227
§ 371(c)(1), (2) Date Mar. 30, 2020,
PCT Pub. No. WO2019/067789, PCT Pub. Date Apr. 4, 2019.
Claims priority of provisional application 62/735,774, filed on Sep. 24, 2018.
Claims priority of provisional application 62/564,232, filed on Sep. 27, 2017.
Prior Publication US 2020/0289576 A1, Sep. 17, 2020
Int. Cl. A61P 3/10 (2006.01); A61K 35/28 (2015.01); A61K 48/00 (2006.01); C07K 14/525 (2006.01); G01N 33/68 (2006.01); A61K 38/00 (2006.01)
CPC A61K 35/28 (2013.01) [A61K 48/005 (2013.01); A61P 3/10 (2018.01); C07K 14/525 (2013.01); G01N 33/68 (2013.01); A61K 38/00 (2013.01); G01N 2333/82 (2013.01)] 17 Claims
 
1. A method for treating complications related to acute or chronic hyperglycemia, the method comprising, in a patient presenting with one or more of said complications selected from diabetes mellitus, insulin resistance, hepatic steatosis, non-alcoholic hepatic steatosis, fibrotic liver disease, vascular disease, or intestinal inflammation:
determining a level of lipocalin-2 (LCN2) in a patient; and
if the level of LCN2 is greater than a predetermined-value, then
administering to the patient a therapeutically effective amount of a selective inhibitor of soluble tumor necrosis factor alpha (solTNF-α), the selective inhibitor of solTNF-a being selected as one which inhibits solTNF-α without inhibiting transmembrane TNF-α, wherein the selective inhibitor of solTNF-a comprises: a dominant negative tumor necrosis factor (DN-TNF)-α protein, a nucleic acid encoding the DN-TNF-α protein, or a combination thereof,
whereby said complications are treated.